肝硬化合并门静脉血栓患者外周血血管内皮生长因子的检测及意义

姚运海; 罗艳; 朱京乐; 甘建和; 赵卫峰

doi:10.3969/j.issn.1001-5256.2020.09.011

肝硬化合并门静脉血栓患者外周血血管内皮生长因子的检测及意义

DOI: 10.3969/j.issn.1001-5256.2020.09.011

1. 苏州大学附属第一医院感染科/肝病ICU
2. 湖南省妇幼保健院医务部

基金项目:

中国肝炎防治基金会-天晴肝病研究基金资助课题(TQGB20200098)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1189
- HTML全文浏览量: 28
- PDF下载量: 120
- 被引次数: 0
出版历程
- 收稿日期: 2020-03-11
- 出版日期: 2020-09-20

Measurement and clinical significance of peripheral blood vascular endothelial growth factor in patients with liver cirrhosis and portal vein thrombosis

Department of Infectious Diseases/Intensive Care Unit of Hepatology,The First Affiliated Hospital of Soochow University
Department of Medical Administration,Hunan Provincial Maternal and Child Health Care Hospital

Research funding:

摘要

摘要: 目的了解血管内皮生长因子（VEGF）在肝硬化合并门静脉血栓（PVT）患者外周血中水平,阐明其水平检测作为肝硬化合并PVT诊断的临床意义。方法选取2017年1月-2019年12月在苏州大学附属第一医院门诊随访或者住院的肝硬化合并PVT患者60例（PVT组）,同期肝硬化合并门静脉高压但无血栓者161例（LC组）。收集入组患者的临床数据,包括性别、年龄、WBC、PLT、TBil、ALT、Alb、PT、INR、AT-Ⅲ水平。双抗体夹心原理酶联免疫吸附法检测血清VEGF水平。正态分布的计量资料2组间比较采用t检验;非正态分布的计量资料2组间比较采用Mann-Whitney U检验;计数资料2组间比较采用χ2检验。相关性分析采用Pearson相关检验。二分类logistic回归分析肝硬化患者发生PVT的危险因素。结果 PVT组与LC组患者基线指标比较,血清VEGF水平差异有统计学意义（Z=-6.682,P <0.05）。不论是Child-Pugh A级还是B+C级,2组患者血清VEGF水平差异均有统计学意义（Z值分别3.749、5.469,P值均<0.05）。逐步logistic回归分...
- 肝硬化 /
- 静脉血栓栓塞 /
- 血管内皮生长因子类
Abstract: Objective To investigate the level of vascular endothelial growth factor( VEGF) in the peripheral blood of patients with liver cirrhosis and portal vein thrombosis( PVT) and its clinical significance in the diagnosis of liver cirrhosis with PVT. Methods A total of 60 patients with liver cirrhosis and PVT who were followed up or hospitalized in the outpatient service of The First Affiliated Hospital of Soochow University from January 2017 to December 2019 were enrolled as PVT group,and 161 patients with liver cirrhosis and portal hypertension who had no thrombi were enrolled as LC group. Related clinical data were collected,including sex,age,white blood cell count,platelet count,total bilirubin,alanine aminotransferase,albumin,prothrombin time,international normalized ratio,and antithrombin Ⅲ． Double-antibody sandwich ELISA was used to measure the serum level of VEGF. The t-test was used for comparison of normally distributed continuous data between two groups,and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. The Pearson correlation test was used for correlation analysis,and a binary logistic regression analysis was used to investigate the risk factors for PVT in patients with liver cirrhosis.Results The comparison of baseline indices showed that there was a significant difference in serum VEGF between the PVT group and the LC group( P < 0. 05). The comparison of the patients with Child-Pugh class A,B or C disease showed that there was a significant difference in serum VEGF between the two groups( Z = 3. 749,5. 469,all P < 0. 05). The stepwise logistic regression analysis showed that only serum VEGF( odds ratio = 1. 004,95% confidence interval: 1. 003-1. 006,P < 0. 001) was an independent risk factor for liver cirrhosis with PVT. Conclusion Patients with liver cirrhosis and PVT tend to have a high level of VEGF in peripheral blood,which provides guidance for clinical diagnosis.
- liver cirrhosis /
- venous thromboembolism /
- vascular endothelial growth factors

HTML全文

参考文献(25)

[1] TSOCHATZIS EA,SENZOLO M,GERMANI G,et al. Systematic review:Portal vein thrombosis in cirrhosis[J]. Aliment Pharmacol Ther,2010,31(3):366-374.

[2] RIBEIRO OD,CANEDO NHS,PANNAIN VL. Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis:Correlation with pathological features[J]. Clinics(Sao Paulo),2016,71(11):639-643.

[3] KIM HO,KIM SK,SON BH,et al. Intraoperative radiofrequency ablation with or without tumorectomy for hepatocellular carcinoma in locations difficult for a percutaneous approach[J].Hepatobiliary Pancreat Dis Int,2009,8(6):591-596.

[4] Chinese Society of Hepatology,Chinese Medical Association.Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol,2019,35(11):2408-2425.(in Chinese)中华医学会肝病学分会．肝硬化诊治指南[J]．临床肝胆病杂志，2019,35(11):2408-2425.

[5] TRIPODI A. Hemostasis in acute and chronic liver disease[J]. Semin Liver Dis,2017,37(1):28-32.

[6] RATNASARI N,NURDJANAH S,SADEWA AH,et al. Difference of polymorphism VEGF-gene rs699947 in Indonesian chronic liver disease population[J]. PLo S One,2017,12(8):e0183503.

[7] GADELHAK NA,GADELHAK SA,EL-MORSI DA,et al.Prognostic significance of three hepatitis markers(p53 antibodies,vascular endothelial growth factors and alpha fetoprotein)in patients with hepatocellular carcinoma[J]. Hepatogastroenterology,2009,56(94-95):1417-1424.

[8] CHO HC,KIM JH,CHA RR,et al. Clinical significance of endothelial progenitor cells in patients with liver cirrhosis with or without hepatocellular carcinoma[J]. Eur J Gastroenterol Hepatol,2020,32(1):87-94.

[9] ZELLER M,KORANDJI C,GUILLAND JC,et al. Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction[J]. Arterioscler Thromb Vasc Biol,2008,28(5):954-960.

[10] KIM TY,LEE JG,SOHN JH,et al. Hepatic venous pressure gradient predicts long-term mortality in patients with decompensated cirrhosis[J]. Yonsei Med J,2016,57(1):138-145.

[11] SIEGHART W,FELLNER S,REIBERGER T,et al. Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma[J]. Dig Liver Dis,2009,41(12):902-906.

[12] LI CP,LEE FY,HWANG SJ,et al. Spider angiomas in patients with liver cirrhosis:Role of vascular endothelial growth factor and basic fibroblast growth factor[J]. World J Gastroenterol,2003,9(12):2832-2835.

[13] SAMOTO K,IKEZAKI K,ONO M,et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors[J]. Cancer Res,1995,55(5):1189-1193.

[14] DINKOVA-KOSTOVA AT,HOLTZCLAW WD,COLE RN,et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants[J]. Proc Natl Acad Sci U S A,2002,99(18):11908-11913.

[15] FERRARA N,GERBER HP,LECOUTER J. The biology of VEGF and its receptors[J]. Nat Med,2003,9(6):669-676.

[16] GELFAND MV,HAGAN N,TATA A,et al. Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding[J]. Elife,2014,3:e03720.

[17] SHWEIKI D,ITIN A,SOFFER D,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis[J]. Nature,1992,359(6398):843-845.

[18] HOEBEN A,LANDUYT B,HIGHLEY MS,et al. Vascular endothelial growth factor and angiogenesis[J]. Pharmacol Rev,2004,56(4):549-580.

[19] TOSON EA,SHIHA GE,ABDELGALEEL AE. Fibrogenic/angiogenic linker for non-invasive assessment of hepatic fibrosis staging in chronic hepatitis C among egyptian patients[J].Ann Hepatol,2017,16(6):862-873.

[20] LI L. Risk factors of portal vein thrombosis in cirrhotic patients from the view of Virchow’s triad[J]. J Prac Hepatol,2015,18(3):325-328.(in Chinese)李玲．从Virchow三要素分析肝硬化患者发生门静脉血栓危险因素[J]．实用肝脏病杂志，2015,18(3):325-328.

[21] Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin:Pulmonary Embolism Prevention(PEP)trial[J]. Lancet,2000,355(9212):1295-1302.

[22] BASILI S,RAPARELLI V,VIOLI F. The coagulopathy of chronic liver disease[J]. N Engl J Med,2011,365(2):147-156.

[23] ZOCCO MA,di STASIO E,de CRISTOFARO R,et al. Thrombotic risk factors in patients with liver cirrhosis:Correlation with MELD scoring system and portal vein thrombosis development[J]. J Hepatol,2009,51(4):682-689.

[24] FEYS HB,CANCIANI MT,PEYVANDI F,et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis[J]. Br J Haematol,2007,138(4):534-540.

[25] NASIM M,MAJID B,TAHIR F,et al. Cavernous transformation of portal vein in the setting of protein C and anti-thrombin III deficiency[J]. Cureus,2019,11(9):e5779.

施引文献

资源附件(0)

访问统计